Physician profile
Dana Mclaughlin
NPI 1346245370
$1,759.01
in general payments reported to CMS, 2019-2025
12 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.49 · 2021: $331 · 2022: $319 · 2023: $310 · 2024: $653 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,091.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $649.97 | 2022-2025 | Infuse, Biotrue One Day, Biotrue |
| Coopervision INC. | $593.72 | 2020-2024 | Misight Contact Lens, Myday Contact Lens |
| Genentech USA, INC. | $150.00 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $125.00 | 2021 | |
| Horizon Therapeutics Plc | $70.44 | 2021-2023 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $64.43 | 2022-2025 | Acuvue |
| Amgen INC. | $19.14 | 2024 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.75 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $17.70 | 2024 | Xdemvy |
| Biotissue Holdings INC. | $17.44 | 2021 | |
| Abbvie INC. | $16.94 | 2022 | |
| Abb Con-Cise Optical Group LLC | $15.48 | 2025 | Spectacle Lenses |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.